Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This 6-month randomized controlled pilot study will determine whether there is some evidence
that cetirizine is better tolerated than diphenhydramine without an increase in
Infusion-Related Reactions (IRRs) in subjects receiving ocrelizumab(OCR) for multiple
sclerosis (MS).